Athenex Announces Appointment of John Koh as a New Board Member
April 02 2019 - 7:00AM
Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical
company dedicated to the discovery, development and
commercialization of novel therapies for the treatment of cancer
and related conditions, today announced the appointment of John Koh
as a Director on Athenex’s Board, effective April 1, 2019.
Mr. Koh joins the Company’s expanded Board of Directors
together with recently announced additions of Dr. John Vierling,
Ms. Stephanie Davis and Mr. Jordan Kanfer.
Dr. Johnson Lau, Chairman and Chief Executive Officer of
Athenex, commented, “We are delighted to welcome another great
addition to Athenex’s Board of Directors. John brings a deep
understanding of finance, law and international markets from his
30-year career in investment banking and law. He has also been an
investor and advisor to buyouts in Singapore, the US, Hong Kong,
Tokyo, and London. We are confident that his experience and
insights will have a meaningful impact on the Company’s growth and
development strategies.”
Mr. Koh added, “I am excited to join this active and influential
Board as it guides Athenex on its path towards realizing the
promise of oral chemotherapy. Patients everywhere will
benefit, and I feel privileged to be part of this company.”
John Koh is an independent director of NSL Ltd.; Mapletree
Industrial Trust, a Singapore listed REIT; Kris Energy; and Aurora
Mobile Limited (JG), a NASDAQ company. He is Chairman of the
Audit Committees of NSL, JG, and Kris Energy; and a Lead
Independent Director for Mapletree REIT and Kris Energy. He
is also a Senior Advisor to Global Counsel, a UK policy advisory
business and Director of its Singapore company. Mr. Koh has
over 30 years of experience in investment banking and law having
been a Managing Director and Senior Advisor of the Goldman Sachs
Group until 2005. Prior to joining Goldman Sachs in 1999, Mr.
Koh spent 19 years as a lawyer, including 7 years with Milbank
Tweed and Paul Weiss, as well as serving in the Singapore
Attorney-General’s Chambers office. Mr. Koh has an active
interest in the arts and the book business as the owner of Bernard
Quaritch Ltd., London’s oldest antiquarian bookseller. He is
also a director of the National Library Board, National Museum and
is on the development board of Oxford University’s Bodleian Library
and advisory committees of the Victoria & Albert Museum and the
Chelsea Physic Garden. Mr. Koh received a Singapore
government scholarship to read economics and law at Trinity
College, Cambridge and is also a graduate of Harvard Law
School. He is also the author of the biography of Singapore’s
first Chief Justice published in 2008 by the Singapore Academy of
Law.
About Athenex, Inc. Founded in
2003, Athenex, Inc. is a global clinical stage
biopharmaceutical company dedicated to becoming a leader in the
discovery, development and commercialization of next generation
drugs for the treatment of cancer. Athenex is organized
around three platforms, including an Oncology Innovation Platform,
a Commercial Platform and a Global Supply Chain Platform. The
Company’s current clinical pipeline is derived from four different
platform technologies: (1) Orascovery, based on non-absorbed
P-glycoprotein inhibitor, (2) Src kinase inhibition, (3) T-cell
receptor-engineered T-cells (TCR-T), and (4) Arginine deprivation
therapy. Athenex’s employees worldwide are dedicated to improving
the lives of cancer patients by creating more active and tolerable
treatments. Athenex has offices
in Buffalo and Clarence, New York; Cranford,
New Jersey; Houston, Texas; Chicago, Illinois; Hong
Kong; Taipei, Taiwan; and multiple locations
in Chongqing, China. For more information, please
visit www.athenex.com.
CONTACTS Investor Relations: Tim McCarthy Managing
Director, LifeSci Advisors, LLC Tel: +1 716-427-2952
Direct: +1 212-915-2564
Athenex, Inc.: Randoll Sze Chief Financial Officer
Email: randollsze@athenex.com Jacqueline Li Corporate
Development and Investor Relations
Email: jacquelineli@athenex.com
Athenex (NASDAQ:ATNX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Athenex (NASDAQ:ATNX)
Historical Stock Chart
From Apr 2023 to Apr 2024